BioCentury | Aug 29, 2019
Distillery Therapeutics

MLANA-loaded nanoparticle vaccine plus mAbs against PD-1 and OX40 to sensitize melanoma to Imbruvica

...DISEASE CATEGORY: Cancer INDICATION: Melanoma Immunization with an MLANA-loaded nanoparticle vaccine in combination with mAbs against...
...compound in Phase I/II through Phase III testing for multiple other cancers. TARGET/MARKER/PATHWAY: Melan-A (MLANA; MART1...
...hflorindo@ff.ulisboa.pt Claire Quang Imbruvica (Brand), PCI-32765 (Compound #), ibrutinib (Generic), Imbruvica (Other) Tel Aviv University University of Lisbon Melan-A (MLANA) (MART1) Programmed...
BioCentury | Dec 21, 2018
Product R&D

Cell therapies seek solid ground

...pulmonary toxicity and edema, followed by a cytokine storm. TCR therapies against the melanoma-associated antigens MART1...
...FMS-like tyrosine kinase 3 ligand HLA - Human leukocyte antigen KRAS (K-Ras) MART1 (MLANA) - Melan-A...
BioCentury | May 23, 2018
Distillery Therapeutics

Transplant

...expression. In mouse models of lymphoblastic leukemia and lymphoma receiving human and allogeneic melan-A (MLANA; MART1)-targeting...
BioCentury | Feb 28, 2018
Distillery Techniques

Biomarkers

...blood samples from patients based on a signature of 19 transcripts -- including melan-A (MLANA; MART1...
...as above email: dhaber@mgh.harvard.edu Jaime De Leon Keytruda Yervoy Harvard University Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) (CTLA4) (CD152) Melan-A (MLANA) (MART1) Melanoma-associated...
BioCentury | Oct 12, 2017
Translation in Brief

Opening doors for I-O

...antitumor responses in patients receiving immunotherapy. In melanoma patients vaccinated with melan-A ( MLANA ; MART1...
...TLR9 agonist CpG7909 (PF-3512676), high serum VEGF-C concentrations were associated with large numbers of circulating MLANA-specific...
...Institute of Technology Lausanne (EPFL) University of Chicago Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) (CTLA4) (CD152) Melan-A (MLANA) (MART1) Programmed...
BioCentury | Oct 3, 2017
Distillery Techniques

Biomarkers

...solid tumors. In sera from 20 metastatic melanoma patients vaccinated with melan-A ( MLANA ; MART1...
...9 (TLR9) agonist CpG7909 , high VEGF-C concentrations were associated with large numbers of circulating MLANA-specific...
...Tuzman Opdivo Yervoy Swiss Federal Institute of Technology Lausanne (EPFL) Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) (CTLA4) (CD152) Melan-A (MLANA) (MART1) Programmed...
BioCentury | Jul 31, 2017
Company News

Management tracks: Aeterna, Microbix, Dimension

Cancer and endocrinology company Aeterna Zentaris Inc. (TSX:AEZS; NASDAQ:AEZS) named Michael Ward CEO. He was chief compliance and legal officer and corporate secretary of Sagent Pharmaceuticals Inc. , which Nichi-Iko Pharmaceutical Co. Ltd. (Tokyo:4541) acquired. Diagnostics...
BioCentury | Jun 7, 2017
Distillery Techniques

Drug delivery

...a fusion of AIDA-I and the CD4 + T cell antigen melan-A ( MLANA ; MART1...
...Singapore email: micliuh@nus.edu.sg Karen Tkach National University of Singapore Bacterial AIDA-I autotransporter (AIDA-I) CD4 CD8 Dopachrome tautomerase (DCT) (TRP-2) (TYRP2) Melan-A (MLANA) (MART1) Tyrosinase...
BioCentury | Mar 17, 2017
Politics, Policy & Law

Carrots & sticks

President Trump’s comments on drug prices, regulatory reforms and tax policy all seem to add up to an attempt to make an offer too good for the pharmaceutical industry to refuse. The implicit deal appears...
BioCentury | Jun 2, 2016
Distillery Therapeutics

Therapeutics: 6-monoacetylmorphine

Neurology INDICATION: Addiction Mouse studies suggest inhibiting the heroin metabolite 6-monoacetylmorphine could help treat heroin addiction. In mice injected with heroin, pretreatment with an antibody against the metabolite decreased opioid-induced locomotive behaviors, levels of 6-monoacetylmorphine...
Items per page:
1 - 10 of 72